Free Trial

Amicus Therapeutics (FOLD) Competitors

Amicus Therapeutics logo
$6.28 -0.03 (-0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$6.27 -0.01 (-0.10%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FOLD vs. HALO, MDGL, RGEN, IONS, ALKS, LGND, BCRX, CLDX, DVAX, and INVA

Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.

Amicus Therapeutics vs. Its Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Halozyme Therapeutics has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$528.29M3.66-$56.11M-$0.09-69.78
Halozyme Therapeutics$1.08B6.68$444.09M$3.7615.63

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amicus Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Halozyme Therapeutics has a net margin of 44.76% compared to Amicus Therapeutics' net margin of -5.41%. Halozyme Therapeutics' return on equity of 136.91% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amicus Therapeutics-5.41% 4.67% 1.05%
Halozyme Therapeutics 44.76%136.91%26.05%

Amicus Therapeutics currently has a consensus price target of $16.22, indicating a potential upside of 158.32%. Halozyme Therapeutics has a consensus price target of $62.70, indicating a potential upside of 6.69%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Amicus Therapeutics is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Halozyme Therapeutics
2 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Halozyme Therapeutics had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 7 mentions for Amicus Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.22 beat Amicus Therapeutics' score of 0.92 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amicus Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
9 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Halozyme Therapeutics beats Amicus Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FOLD vs. The Competition

MetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.94B$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio-69.7720.7327.9019.95
Price / Sales3.66321.12442.19102.72
Price / CashN/A43.2336.5558.97
Price / Book9.668.308.635.90
Net Income-$56.11M-$55.19M$3.24B$258.42M
7 Day Performance-0.16%5.07%3.22%1.94%
1 Month Performance9.98%17.61%10.72%12.02%
1 Year Performance-39.32%7.03%34.94%20.81%

Amicus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FOLD
Amicus Therapeutics
4.0443 of 5 stars
$6.28
-0.5%
$16.22
+158.3%
-38.8%$1.94B$528.29M-69.77480News Coverage
Upcoming Earnings
HALO
Halozyme Therapeutics
4.8494 of 5 stars
$57.65
+0.9%
$62.50
+8.4%
+5.7%$7.10B$1.02B15.33390Positive News
MDGL
Madrigal Pharmaceuticals
4.2717 of 5 stars
$319.87
+1.4%
$420.63
+31.5%
+9.7%$7.10B$180.13M-17.7290Insider Trade
RGEN
Repligen
4.6091 of 5 stars
$121.33
-6.8%
$170.75
+40.7%
-11.7%$6.82B$650.43M-269.621,778Upcoming Earnings
Analyst Upgrade
Analyst Revision
IONS
Ionis Pharmaceuticals
4.572 of 5 stars
$42.55
+2.0%
$58.25
+36.9%
-16.0%$6.77B$717.25M-14.231,069News Coverage
Upcoming Earnings
Analyst Revision
ALKS
Alkermes
4.7768 of 5 stars
$29.69
-1.9%
$40.00
+34.7%
+8.8%$4.90B$1.51B14.211,800Upcoming Earnings
Analyst Forecast
LGND
Ligand Pharmaceuticals
4.2568 of 5 stars
$126.92
+4.3%
$147.17
+16.0%
+33.1%$2.45B$181.49M-17.8380
BCRX
BioCryst Pharmaceuticals
4.5177 of 5 stars
$8.96
+2.3%
$16.70
+86.4%
+15.3%$1.87B$450.71M-34.46530
CLDX
Celldex Therapeutics
1.7927 of 5 stars
$23.36
+2.0%
$50.11
+114.5%
-38.5%$1.55B$7.02M-8.65150
DVAX
Dynavax Technologies
4.3973 of 5 stars
$10.74
+1.5%
$24.00
+123.5%
+3.7%$1.29B$294.62M-20.65350Positive News
INVA
Innoviva
4.071 of 5 stars
$19.58
+4.3%
$40.33
+106.0%
+8.2%$1.23B$358.71M-19.39100Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:FOLD) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners